• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS ELECSYS INSULIN; IMMUNOREACTIVE INSULIN TEST SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS ELECSYS INSULIN; IMMUNOREACTIVE INSULIN TEST SYSTEM Back to Search Results
Catalog Number 12017547122
Device Problems Incorrect Measurement (1383); High Test Results (2457)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 08/29/2023
Event Type  malfunction  
Event Description
The initial reporter complained of high results for 2 samples from 1 patient tested for elecsys insulin (insulin) on a cobas e 411 immunoassay analyzer.On (b)(6) 2023 the patient had an insulin result of 962.8 uu/ml with a data flag from the e411 analyzer.The repeat result was 960.8 uu/ml with a data flag.On (b)(6) 2023 a new sample was obtained and the result from the e411 analyzer was 966.0 uu/ml with a data flag.This sample was sent to another laboratory where the result from the maglumi method was 99.61 uu/ml and the result from the atellica method was 31.03 uu/ml.
 
Manufacturer Narrative
The e411 analyzer serial number is (b)(6).Qc was acceptable.On (b)(6) 2023 the customer treated the sample from (b)(6) 2023 with polyethylene glycol to test for interference and the result was 40.62 uu/ml.The investigation is ongoing.
 
Manufacturer Narrative
The insulin result from the atellica method of 31.03 uu/ml was believed to be correct as this coincides with the patient's clinical history.The calibration data provided from 06-aug-2023 was acceptable.Qc data provided between 05-jun-2023 and 05-aug-2023 was acceptable.The investigation determined the event was consistent with the presence of anti-insulin antibodies in the patient sample which are recognized by the elecsys insulin assay.This is confirmed by the result received by the customer after treating the sample with polyethylene glycol.A general reagent issue can be excluded as the provided quality control data is within expectations.Product labeling states: "samples from patients treated with bovine, porcine or human insulin sometimes contain anti-insulin antibodies which can affect the test results." the investigation did not identify a product problem.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELECSYS INSULIN
Type of Device
IMMUNOREACTIVE INSULIN TEST SYSTEM
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
Manufacturer (Section G)
ROCHE DIAGNOSTICS GMBH
sandhofer strasse 116
mannheim (baden-wurttemberg) 68305
GM   68305
Manufacturer Contact
amy nelson
9115 hague road
indianapolis, IN 46250
MDR Report Key17817409
MDR Text Key324252060
Report Number1823260-2023-03107
Device Sequence Number1
Product Code CFP
UDI-Device Identifier04015630913060
UDI-Public04015630913060
Combination Product (y/n)Y
Reporter Country CodeAR
PMA/PMN Number
K001104
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 10/20/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/26/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/31/2023
Device Catalogue Number12017547122
Device Lot Number63343603
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/27/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ASPART INSULIN ¿ 3X/DAY; NPH OR ISOPHANE INSULIN ¿ 3X DAY; UNSPECIFIED CHOLESTEROL MEDICATION; UNSPECIFIED HYPERTENSION MEDICATION
-
-